Navigation Links
Cepheid Reports 2013 Second Quarter Results
Date:7/18/2013

y, total sales were, in millions: Three Months Ended June 30,20132012ChangeNorth AmericaClinical

$
49.9$
47.55%Non-Clinical & Other

7.59.5-21%Total North America57.457.01%InternationalClinical

37.622.269%Non-Clinical & Other

1.01.8-41%Total International38.624.061%Total Sales$
96.0$
81.019%


  • During the quarter, Cepheid installed a total of 156 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 279 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,552 GeneXpert systems have been placed worldwide as of June 30, 2013.
  • GAAP gross margin on sales was 45% and non-GAAP gross margin on sales was 47%, which compares to 57% and 58%, respectively, in the second quarter of 2012.  Excluding the impact of the unanticipated inventory reserve of approximately $3.0 million, GAAP gross margin on sales was 48% and non-GAAP gross margin on sales was 50%.
  • Cash and cash equivalents were $85.0 million as of June 30, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company's full year guidance has been revised to reflect additional investment in manufacturing operations to fully prepare the Company to effectively manage growing demand and expected revenue mix between Commercial Clinical and HBDC.  With these points in mind, the Company now expects:

  • Total revenue in the range of $380 to $385 million;
  • Net loss in a range from $(0.30) to $(0.27) per share; and
  • Non-GAAP net income in the range of $0.18 to $0.21 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cepheid Welcomes Senior Vice President of Human Resources
    2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    3. Cepheid to Webcast Upcoming Financial Presentations
    4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    8. Cepheid Reports 2012 Second Quarter Results
    9. Cepheid Announces Board of Directors Changes
    10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    11. Cepheid Reports 2013 First Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
    (Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
    (Date:4/21/2015)... 2015 A leading manufacturer of stainless ... to discuss its custom fabrication services today at INTERPHEX ... which launched just prior to the INTERPHEX event. The ... 22 and 23) at the Javits Center in New ... world’s largest and most innovative pharmaceutical and biotech firms ...
    (Date:4/20/2015)... Winston-Salem, NC and Champaign, IL (PRWEB) April 20, 2015 ... announced today the establishment of its 12th clinical research ... 2015, PMG Research has assumed operation of the clinical ... IL, expanding PMG’s footprint outside the Southeast to a ... site within a 150 multi-specialty physician practice enhances PMG’s ...
    Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3
    ... Phase 1 clinical studies support advancement to Phase 2 ... Roche polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... four abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) ... American Association for the Study of Liver Diseases,(AASLD, Oct. ...
    ... new screening platform for antibody therapeutics, BASEL, ... today that it has completed the acquisition of ... of ARIUS Research (TSX: ARI). On,September 19th, the ... previously approved by the security holders and announced ...
    ... signing to follow his presentation, WASHINGTON, Sept. ... global marketplace, and the role of,financing are focus ... presentations will focus on the convergence of the,MedTech ... patient monitoring,technologies, critical issues to consider when entering ...
    Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Roche completes acquisition of ARIUS 2Former Speaker of the House Newt Gingrich Featured Wednesday 2
    (Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
    (Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
    (Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
    Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
    ... upcoming paper from Dr. David Wassarman (University of Wisconsin ... 1 issue of G&D lends new insight into the ... (A-T) is a rare, genetic immunodeficiency disease that affects ... cancer predisposition. A-T is caused by recessive mutations in ...
    ... to designing something, its hard to find a better ... principle, a diverse, interdisciplinary group of researchers at the ... to synthesize magnetic nanoparticles that could be used for ... high-density memory devices, or as magnetic seals in motors. ...
    ... nature vs. nurture debate is familiar to most people, ... two. A new paper published this week in the ... similar balance between the genes we inherit—nature—and the environment—nurture—in ... the age of personal genomics, in which each of ...
    Cached Biology News:Researchers mimic bacteria to produce magnetic nanoparticles 2Researchers mimic bacteria to produce magnetic nanoparticles 3
    X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
    ...
    Recalibration of HL-2000-CAL products...
    Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
    Biology Products: